US Bancorp’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

US Bancorp’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,018	Closed	-$23K	–	3766
2017 Q3	$23K	Hold	2,018	–	–	﹤0.01%	2852
2017 Q2	$23K	Sell	2,018 -41	-2%	-$410	﹤0.01%	2843
2017 Q1	$20K	Buy	2,059 +58	+3%	+$579	﹤0.01%	2848
2016 Q4	$22K	Buy	+2,001	New	+$20K	﹤0.01%	2801

US Bancorp's SCLN Position: Q4 2017 in Review

US Bancorp sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 2,018 shares — an estimated $23K sold.

US Bancorp first reported a position in SCLN in Q4 2016 and held it in 4 quarters. The position peaked at $23K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

US Bancorp reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
US Bancorp sold 2,018 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $23K.
US Bancorp first reported a position in Sciclone Pharmaceuticals Inc in Q4 2016 and held it in 4 quarters.
US Bancorp's Sciclone Pharmaceuticals Inc position peaked at $23K in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on US Bancorp's 13F filing for Q4 2017, filed 2 Feb 2018.